Refine by
T Cell Receptor Articles & Analysis
38 news found
With an unwavering commitment to innovation and precision, CD Genomics continues to redefine the genomics research landscape. TCR-Seq, short for T Cell Receptor Sequencing, is an instrumental tool that enables scientists and researchers to decode the intricate tapestry of T cell populations within the immune ...
In the rapidly evolving field of drug delivery systems, novel therapies are continuously being developed to enhance the effectiveness and precision of treatment. CAR-T (chimeric antigen receptor T-cell) and CAR-NK (chimeric antigen receptor natural killer cell) therapies involve genetically ...
HPK1 kinase activity suppresses the immune functions of a wide range of cells including T cells and dendritic cells (DCs) 1. Therefore, inhibiting HPK1 activity serves as a promising approach for cancer immunotherapy. ...
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of ...
The capital raise enables Carina to complete its Investigational New Drug (IND) enabling studies and initiate a CAR-T clinical trial of our LGR5 CAR-T cell for patients with advanced colorectal (bowel) cancer. ...
Leading pharmaceutical research and development (R&D) teams can leverage MiXCR 4.0 for drug discovery pipelines, and for analyzing DNA sequencing data unraveling genomic information about antibodies, T-cell, and B-cell receptors. The initial stage of molecular identification during pre-clinical research remains a ...
(Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, for the treatment of BK viremia (BKV) in adult kidney transplant ...
ByKalaris
Date and Time: May 18, 2022, 5:30 p.m. to 6:30 p.m. ET Title: Armoring T-cells with regulatable, membrane tethered cytokines using improved drug-responsive domain technology (cytoDRiVE®) Presenter: Dr. ...
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually at the ...
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the fiscal quarter ...
The data demonstrate that CB-011 CAR-T cells are cytotoxic against BCMA-expressing tumor cells and are resistant to killing by both allogeneic T cells and natural killer (NK) cells. ...
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced its financial results for the fiscal year 2021 ended December 31, 2021 and provided a ...
Of the nine patients with available T cell receptor sequencing data, all had detectable posoleucel cells, with confirmed persistence for up to 14 weeks after the last infusion. A preliminary assessment of virus-specific T cell activity against the infecting virus by IFN-γ ELIspot ...
ByKalaris
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“the Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the first patient was dosed in the KEYNOTE-B79 Phase 1b trial (NCT04991948). ...
(NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE: BMY), today announced that they have entered into a license, development and commercialization agreement (the “agreement”) for Immatics’ TCR ...
The data demonstrated that equipping IMA203-T cells with CD8αβ, a T cell co-receptor, enhances anti-tumor activity of the engineered T cells. ...
In vivo data presented at the SITC annual meeting highlight the potential of T-knife’s lead product candidate TK-8001, a TCR engineered T cell therapy (TCR-T) that is being developed to treat MAGE-A1 positive solid tumors. ...
Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells Data suggests that addition of AKT inhibitor (AKTi) during manufacture can remodel gene expression towards better proliferation or better ...
The symposium will focus on the emerging landscape of technologies leveraging gamma delta T cells for anticancer therapeutics and will be moderated by Andrea van Elsas, Ph.D., chair, scientific advisory board at LAVA, and will feature presentations from leading experts in the field of gamma delta T cell immunity. ...
Afami-cel SPEAR T-cells target MAGE-A4+ tumors. MAGE-A4 is highly expressed in synovial sarcoma and MRCLS in the context of HLA-A*02. ...